YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

Effect of Long-Term Carbamazepine Therapy on Serum Lipids, Vitamin B12 and Folic Acid Levels in Children

dc.authorscopusid 7003892943
dc.authorscopusid 7101974609
dc.authorscopusid 6602193576
dc.contributor.author Deda, G.
dc.contributor.author Çaksen, H.
dc.contributor.author Içaǧasioǧlu, D.
dc.date.accessioned 2025-05-10T17:06:17Z
dc.date.available 2025-05-10T17:06:17Z
dc.date.issued 2003
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp Deda G., Department of Pediatrics, Faculty of Medicine, Ankara University, Ankara, Turkey; Çaksen H., Department of Pediatrics, Faculty of Medicine, Yuzuncu Yil University, Van, K. Karabekir C. Golbasi 3. S., Turkey; Içaǧasioǧlu D., Department of Pediatrics, Faculty of Medicine, Ankara University, Ankara, Turkey en_US
dc.description.abstract Serum triglycerides, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), vitamin B12 and folic acid levels were studied in 16 children with epilepsy who had been receiving carbamazepine (CBZ), and in 16 healthy children. Our purpose was to determine whether there was any effect of CBZ therapy on serum lipids, vitamin B12 and folic acid levels. Age ranged from 5 to 19 years (12.25 ± 3.79 years) and 5.5 to 18 years (12.16 ± 3.53 years) in the study and control groups, respectively. The duration of CBZ therapy in the patients was between 1 and 4.5 years (3.01 ± 1.04 years). Serum CBZ level varied between 4 and 12 μg/ml (6.26 ± 2.07 μg/ml). There was no statistically significant difference in serum triglycerides, TC, HDL-C, LDL-C, VLDL-C or vitamin B12. However, mean folic acid level was found to be lower in the study group than that of the control group (p <0.05). Nonetheless, serum folic acid levels were within the normal range in all patients. Our study demonstrated that CBZ therapy does not affect serum lipids, vitamin B12 and folic acid levels, and may safely be used with regard to these parameters in children.; Indications:16 patients with epilepsy.; Results:There was no statistical difference in serum TG, TC, HDL-C, LDL-C, VLDL- C and vitamin B12. Mean folic acid level was found to be lower in the Tegretol group than that of the control group. Serum folic acid levels were within the normal range in all patients. Serum Tegretol ranged from 4 -12 mcg/ml (mean 6.26 mcg/ml).; Patients:32 patients. Tegretol group: 16 patients, 9 males and 7 female, aged 5- 19 years (12.25 ± 3.79). Control group: 16 healthy subjects, 7 male and 9 female, aged 5.5-18 years (12.16 ± 3.53).; TypeofStudy:The effect of Tegretol therapy on the serum lipid profile, cyanocobalamin (vitamin B12), and folic acid levels in children with epilepsy was studied.; DosageDuration:Serum levels ranged from 4-12 μg/ml (6.26 ± 2.07 μg/ml). Dosage not stated. Duration: between 1-4.5 years (3.01 ± 1.04).; AdverseEffects:No adverse events were mentioned.; AuthorsConclusions:In conclusion, our findings showed that CBZ did not affect the serum lipid profile or serum B12 and folic acid levels, and may be safely used with regard to these parameters in children.; FreeText:Tests: fasting serum levels of triglycerides (TG), total cholesterol (TC), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), vitamin B12, and folic acid, and serum Tegretol levels in the patient group. Serum TG, TC and HDL-C concentrations were measured by a colometric photometric method. Serum vitamin B12 and folic acid levels were measured by radioimmunoassay. Serum Tegretol (carbamazepine) level was measured by fluorescence polarization immunoassay using Abbott Laboratories Diagnostics kits. en_US
dc.description.woscitationindex Science Citation Index Expanded
dc.identifier.doi 10.1515/JPEM.2003.16.2.193
dc.identifier.endpage 196 en_US
dc.identifier.issn 0334-018X
dc.identifier.issue 2 en_US
dc.identifier.pmid 12713256
dc.identifier.pmid 12713256
dc.identifier.scopus 2-s2.0-0042415497
dc.identifier.scopusquality Q4
dc.identifier.startpage 193 en_US
dc.identifier.uri https://doi.org/10.1515/JPEM.2003.16.2.193
dc.identifier.uri https://hdl.handle.net/20.500.14720/6382
dc.identifier.volume 16 en_US
dc.identifier.wos WOS:000184293800008
dc.identifier.wosquality Q4
dc.language.iso en en_US
dc.publisher Walter de Gruyter GmbH en_US
dc.relation.ispartof Journal of Pediatric Endocrinology and Metabolism en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Carbamazepine en_US
dc.subject Folic Acid en_US
dc.subject Lipids en_US
dc.title Effect of Long-Term Carbamazepine Therapy on Serum Lipids, Vitamin B12 and Folic Acid Levels in Children en_US
dc.type Article en_US

Files